… have EGFR mutations. We therefore designed the LUX-Lung 2 phase 2 study to further
assess the efficacy of afatinib in patients with lung adenocarcinoma containing EGFR mutations. …

… Here, we report mature overall survival results from the individual LUX-Lung 3 and LUX-Lung
6 studies. Additionally, to provide more accurate estimates of the overall effect of afatinib …

… Here, we describe the activity of afatinib in patients with uncommon EGFR mutations in the
LUX-Lung clinical trials programme, with data from the non-randomised phase 2 LUX-Lung 2 …

… Progression-free and overall survival for subgroups with varying degrees of expected
clinical enrichment for EGF receptor mutations within the LUX-Lung 1 clinical trial. …

… E709X) and 59% (for G719X) were observed in patients with complex mutations. Combined
analysis of LUX-lung 2, 3 and 6 trials demonstrated that ORR for G719X tumors treated with …

… This article describes the findings of two large, randomised Phase III trials (LUX-Lung 3 (LL3)
and LUX-Lung 6 (LL6)), which compared the ErbB family blocker afatinib with standard …

… In this study, we utilized the phase III LUX-Lung 3 and LUX-Lung 6 data sets to assess the
activity of afatinib in the prespecified subset of patients with EGFR mutation–positive NSCLC …

… growth factor receptor EGFR/HER1 mutations represent a unique … IIIB/IV lung adenocarcinoma,
EGFR mutations in exons 18–… Results: 444 patients were tested for EGFR mutations and …

… with advanced adenocarcinoma of the lung and EGFR mutation. Afatinib is clearly superior
… common activating mutations in exons 19 and 21 (Table 1). In this regard, the LUX-Lung 3 …

… In prespecified analyses of the LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) trials, afatinib also
… harboring EGFR Del19 mutations. The recent head-to-head randomized trials, LUX-Lung 7 (…